Bart is a biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. He has extensive experience in working with R&D  based companies in several therapeutic areas, including cancer, inflammatory diseases and fibrosis. Bart Wuurman has contributed to successful biotech company exits in the UK and in the Netherlands and he was responsible for pharma licensing deals worth over $700 million. Bart was CEO of De Novo pharmaceuticals (UK), AM-Pharma (NL), Lanthio Pharma (NL) and Lyramid (Australia) and is Director of Hercules Pharmaceuticals. Bart was also Managing Director of DDF Ventures, a life-science focused venture fund with a portfolio of start-up companies in The Netherlands.